https://ir.tuhurabio.com/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/_0b4577ffa47b2b3b138998038d9a2607/tuhurabio/files/theme/images/logo-sm.png Equisolve Investor Relations Suite https://ir.tuhurabio.com/news-events/press-releases/detail/41/tuhura-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-corporate-update Wed, 01 Apr 26 07:45:00 -0400 https://ir.tuhurabio.com/news-events/press-releases/detail/41/tuhura-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-corporate-update https://ir.tuhurabio.com/news-events/press-releases/detail/40/craig-tendler-m-d-jnjs-former-global-head-of-oncology-clinical-development-to-lead-tuhura-biosciences-vista-program-in-aml-and-other-blood-related-cancers Mon, 23 Mar 26 07:45:00 -0400 https://ir.tuhurabio.com/news-events/press-releases/detail/40/craig-tendler-m-d-jnjs-former-global-head-of-oncology-clinical-development-to-lead-tuhura-biosciences-vista-program-in-aml-and-other-blood-related-cancers https://ir.tuhurabio.com/news-events/press-releases/detail/39/tuhura-biosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement Fri, 27 Feb 26 07:30:00 -0500 https://ir.tuhurabio.com/news-events/press-releases/detail/39/tuhura-biosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement https://ir.tuhurabio.com/news-events/press-releases/detail/38/tuhura-biosciences-announces-participation-in-upcoming-investor-conferences Tue, 24 Feb 26 17:20:00 -0500 https://ir.tuhurabio.com/news-events/press-releases/detail/38/tuhura-biosciences-announces-participation-in-upcoming-investor-conferences https://ir.tuhurabio.com/news-events/press-releases/detail/37/tuhura-files-investigational-new-drug-application-for-tbs-2025-in-the-treatment-of-blood-related-cancers Tue, 17 Feb 26 07:45:00 -0500 https://ir.tuhurabio.com/news-events/press-releases/detail/37/tuhura-files-investigational-new-drug-application-for-tbs-2025-in-the-treatment-of-blood-related-cancers https://ir.tuhurabio.com/news-events/press-releases/detail/36/tuhura-biosciences-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference Thu, 12 Feb 26 07:45:00 -0500 https://ir.tuhurabio.com/news-events/press-releases/detail/36/tuhura-biosciences-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference https://ir.tuhurabio.com/news-events/press-releases/detail/35/tuhura-biosciences-received-fda-orphan-drug-designation-for-ifx-2-0-for-the-treatment-of-stage-iib-to-stage-iv-cutaneous-melanoma Mon, 02 Feb 26 07:45:00 -0500 https://ir.tuhurabio.com/news-events/press-releases/detail/35/tuhura-biosciences-received-fda-orphan-drug-designation-for-ifx-2-0-for-the-treatment-of-stage-iib-to-stage-iv-cutaneous-melanoma https://ir.tuhurabio.com/news-events/press-releases/detail/34/tuhura-biosciences-announces-its-release-of-kintaras-contingent-value-right-cvr-as-kintaras-rem-001-meets-primary-safety-endpoint-achieving-contractual-milestone Mon, 15 Dec 25 07:50:00 -0500 https://ir.tuhurabio.com/news-events/press-releases/detail/34/tuhura-biosciences-announces-its-release-of-kintaras-contingent-value-right-cvr-as-kintaras-rem-001-meets-primary-safety-endpoint-achieving-contractual-milestone https://ir.tuhurabio.com/news-events/press-releases/detail/33/tuhura-biosciences-provides-corporate-update-following-recent-financing Thu, 11 Dec 25 07:30:00 -0500 https://ir.tuhurabio.com/news-events/press-releases/detail/33/tuhura-biosciences-provides-corporate-update-following-recent-financing https://ir.tuhurabio.com/news-events/press-releases/detail/32/tuhura-biosciences-inc-announces-15-6-million-registered-direct-offering Tue, 09 Dec 25 09:49:00 -0500 https://ir.tuhurabio.com/news-events/press-releases/detail/32/tuhura-biosciences-inc-announces-15-6-million-registered-direct-offering